GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008, CA. Cancer J Clin 2008; 58: 71–96
   PubMed Web of Science ®Google Scholar
• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193–207
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Lister T A. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005; 18: 1–10
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Rranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Deans J P. CD20: B-cell antigen and therapeutic target. Therapeutic Strategies in Lymphoid Malignancy: An Immunotherapeutic Approach, P Hillmen, T E Witzig. Informa Healthcare, London, UK 2005; 33–42
   Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629–3636
   PubMed Web of Science ®Google Scholar
• Chow K U, Sommerlad W D, Boehrer S, Schneider B, Seipelt G, Rummel M J, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33–43
   PubMed Web of Science ®Google Scholar
• Jazirehi A R, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121–2143
   PubMed Web of Science ®Google Scholar
• Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30: 3–8
   PubMed Web of Science ®Google Scholar
• Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
   PubMed Web of Science ®Google Scholar
• Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204: 55–63
   PubMed Web of Science ®Google Scholar
• Cragg M S, Morgan S M, Chan H T, Morgan B P, Filatov A V, Johnson P W, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045–1052
   PubMed Web of Science ®Google Scholar
• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 2–9
   PubMed Web of Science ®Google Scholar
• Clynes R A, Towers T L, Presta L G, Ravetch J V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443–446
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Elsasser D, Dechant M, Repp R, Gramatzki M, Glennie M J, et al. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 2001; 248: 103–111
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754–758
   PubMed Web of Science ®Google Scholar
• Hofmeister J K, Cooney D, Coggeshall K M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26: 133–143
   PubMed Web of Science ®Google Scholar
• Selenko N, Maidic O, Draxier S, Berer A, Jager U, Knapp W, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15: 1619–1626
   PubMed Web of Science ®Google Scholar
• Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J Clin Immunol 2002; 22: 124–130
   PubMed Web of Science ®Google Scholar
• Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma––a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095
   PubMed Web of Science ®Google Scholar
• Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister F B, Grillo-Lopez A J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26: 79–87
   PubMed Web of Science ®Google Scholar
• Davis T A, White C A, Grillo-Lopez A J, Velasquez W S, Link B, Maloney D G, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group. Ann Hematol 2000; 79: 493–500
   PubMed Web of Science ®Google Scholar
• Piro L D, White C A, Grillo-Lopez A J, Janakiraman N, Saven A, Beck T M, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655–661
   PubMed Web of Science ®Google Scholar
• Foran J M, Rohatiner A Z, Cunningham D, Popescu R A, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–324
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Burris H A, III, Morrissey L H, Litchy S, Scullin Jr DC, Bearden J D, III, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–3056
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106
   PubMed Web of Science ®Google Scholar
• Conconi A, Martinelli G, Thieblemont C, Ferreri A J, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741–2745
   PubMed Web of Science ®Google Scholar
• Witzig T E, Vukov A M, Habermann T M, Geyer S, Kurtin P J, Friedenberg W R, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central cancer treatment group. J Clin Oncol 2005; 23: 1103–1108
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris H A, III, Scullin Jr DC, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, et al. Stage IV indolent lymphoma: a randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab, with interferon maintenance. Ann Oncol 2005; 16(suppl 5)v109, [abstract 247]
   Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Grabstein K H, Urdal D L, Tushinski R J, Mochizuki D Y, Price V L, Cantrell M A, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232: 506–508
   PubMed Web of Science ®Google Scholar
• Bussolino F, Wang J M, Defilippi P, Turrini F, Sanavio F, Edgell C J, et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–473
   PubMed Web of Science ®Google Scholar
• Bot F J, van Eijk L, Schipper P, Lowenberg B. Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates immature marrow precursors but no CFU-GM, CFU-G, or CFU-M. Exp Hematol 1989; 17: 292–295
   PubMed Web of Science ®Google Scholar
• Coleman D L, Chodakewitz J A, Bartiss A H, Mellors J W. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988; 72: 573–578
   PubMed Web of Science ®Google Scholar
• Chen B D, Mueller M, Chou T H. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988; 141: 139–144
   PubMed Web of Science ®Google Scholar
• Charak B S, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993; 81: 3474–3479
   PubMed Web of Science ®Google Scholar
• Masucci G, Wersall P, Ragnhammar P, Mellstedt H. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 1989; 29: 288–292
   PubMed Web of Science ®Google Scholar
• Steis R G, VanderMolen L A, Longo D L, Clark J W, Smith J W, Kopp W C, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst 1990; 82: 697–703
   PubMed Web of Science ®Google Scholar
• Young D A, Lowe L D, Clark S C. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990; 145: 607–615
   PubMed Web of Science ®Google Scholar
• Robin G, Markovich S, Athamna A, Keisari Y. Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 1991; 10: 257–263
   PubMedGoogle Scholar
• Morrissey P J, Bressler L, Park L S, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987; 139: 1113–1119
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 177–186
   PubMedGoogle Scholar
• Gazitt Y, Shaughnessy P, Liu Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 167–176
   PubMedGoogle Scholar
• Shaughnessy P J, Bachier C, Nanez A, Akay C, LeMaistre C F, Gazitt Y. Comparison between G-CSF and GM-CSF for mobilization of dendritic cells, CD34+ cells, and CD3+ cells in normal donors. Blood 2004; 104: 785a, [abstract 2870]
   Google Scholar
• Santoli D, Clark S C, Kreider B L, Maslin P A, Rovera G. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol 1988; 141: 519–526
   PubMed Web of Science ®Google Scholar
• Tarr P E. Granulocyte-macrophage colony-stimulating factor and the immune system. Med Oncol 1996; 13: 133–140
   PubMed Web of Science ®Google Scholar
• Blanchard D K, Djeu J Y. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis. J Leukoc Biol 1991; 50: 28–34
   PubMed Web of Science ®Google Scholar
• Arnaout M A, Wang E A, Clark S C, Sieff C A. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78: 597–601
   PubMed Web of Science ®Google Scholar
• Ruef C, Coleman D L. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12: 41–62
   PubMedGoogle Scholar
• Broxmeyer H E, Cooper S, Williams D E, Hangoc G, Gutterman J U, Vadhan-Raj S. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1988; 16: 594–602
   PubMed Web of Science ®Google Scholar
• Venugopal P, Sivaraman S, Huang X K, Nayini J, Gregory S A, Preisler H D. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24: 411–415
   PubMed Web of Science ®Google Scholar
• Connor R I, Shen L, Fanger M W. Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. J Immunol 1990; 145: 1483–1489
   PubMed Web of Science ®Google Scholar
• Keler T, Wallace P K, Vitale L A, Russoniello C, Sundarapandiyan K, Graziano R F, et al. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol 2000; 164: 5746–5752
   PubMed Web of Science ®Google Scholar
• Ravandi F. Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006; 20: 563–571
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F J, Jupudy V, Reising S, Repasky E A, Czuczman M S. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46: 1775–1784
   PubMed Web of Science ®Google Scholar
• Masucci G, Ragnhammar P, Wersall P, Mellstedt H. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 1990; 31: 231–235
   PubMed Web of Science ®Google Scholar
• Ragnhammar P. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Med Oncol 1996; 13: 167–176
   PubMed Web of Science ®Google Scholar
• Hjelm S A, Ragnhammar P, Fagerberg J, Frodin J, Goldinger M, Koldestam H, et al. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol Immunother 1999; 48: 463–470
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Fagerberg J, Frodin J E, Hjelm A L, Lindemalm C, Magnusson I, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma–long-lasting, complete remissions can be induced. Int J Cancer 1993; 53: 751–758
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Masucci G, Frodin J E, Hjelm A L, Mellstedt H. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunol Immunother 1992; 35: 158–164
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Fagerberg J, Frodin J E, Wersall P, Hansson L O, Mellstedt H. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995; 40: 367–375
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Liu N, Poindexter N, Grimm E, Fayad L, Hagemeister F, et al. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Ann Oncol 2005; 16(suppl 5)v68, [abstract 104]
   Google Scholar
• Rossi J F, Lu Z Y, Quittet P, Baudard M, Rouille V, Klein B. Rituximab activity is potentiated by GM-CSF in patients with relapsed, follicular lymphoma: results of a phase II study. Blood 2005; 106: 684a, [abstract 2432]
   Google Scholar
• Ferrajoli A, O'Brien S M, Faderl S H, Wierda W G, Schlette E, Jorgensen J L, et al. The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 2006; 24(suppl)361s, [abstract 6602]
   Google Scholar
• Venugopal P, Wooldridge J, Yunus F, Adler S S, Shammo J M, Enschede S H, et al. Chemoimmunotherapy with combination of rituximab, GMCSF and CHOP in patients with previously untreated aggressive non-Hodgkin's lymphoma. Blood 2003; 102: 302b, [abstract 4930]
   Google Scholar
• Venugopal P, Gregory S A, Showel J L, Enschede S H, Shammo J M, O'Brien T M, et al. ESHAP combined with rituximab and GMCSF is highly active in relapsed/refractory aggressive lymphoma. Blood 2003; 102: 307b, [abstract 4950]
   Google Scholar
• Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 627–636
   PubMed Web of Science ®Google Scholar